Search Results | Molecular Cancer Therapeutics | American Association for Cancer Research

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Colchicine-binding site agent CH-2-77 as a potent tubulin inhibitor suppressing triple-negative breast cancer

Shanshan Deng, Raisa I. Krutilina, Kelli L. Hartman, Hao Chen, Deanna N. Parke, Rui Wang, Foyez Mahmud, Dejian Ma, Pradeep B. Lukka, Bernd Meibohm, Tiffany N. Seagroves, Duane D. Miller, Wei Li

Mol Cancer Ther molcanther.0899.2021.

DOI: https://doi.org/10.1158/1535-7163.MCT-21-0899

Published: 02 May 2022

View article

Includes: Supplementary data

Journal Articles

An Orally Available Tubulin Inhibitor, VERU-111, Suppresses Triple-Negative Breast Cancer Tumor Growth and Metastasis and Bypasses Taxane Resistance

Shanshan Deng, Raisa I. Krutilina, Qinghui Wang, Zongtao Lin, Deanna N. Parke, Hilaire C. Playa, Hao Chen, Duane D. Miller, Tiffany N. Seagroves, Wei Li

Mol Cancer Ther (2020) 19 (2): 348–363.

DOI: https://doi.org/10.1158/1535-7163.MCT-19-0536

Published: 06 February 2020

View article

Includes: Supplementary data

Journal Articles

Abstract B037: Potential next-generation androgen receptor-targeted therapeutic for enzalutamide-resistant prostate cancer; In vivo characterization in immune-compromised SRG rats

Suriyan Udhayasuriyan Ponnusamy, Fallon K Noto, Bisoye Towobola Adedeji, Yali He, Dong-Jin Hwang, Sam Moody, Thirumagal Thiyagarajan, Tseten Yeshi Jamling, Duane D Miller, Ramesh Narayanan

Mol Cancer Ther (2019) 18 (12_Supplement): B037.

DOI: https://doi.org/10.1158/1535-7163.TARG-19-B037

Published: 01 December 2019

View article

Journal Articles

Synergistic Combination of Novel Tubulin Inhibitor ABI-274 and Vemurafenib Overcomes Vemurafenib Acquired Resistance in BRAF^V600E Melanoma

Jin Wang, Jianjun Chen, Duane D. Miller, Wei Li

Mol Cancer Ther (2014) 13 (1): 16–26.

DOI: https://doi.org/10.1158/1535-7163.MCT-13-0212

Published: 13 January 2014

View article

Includes: Supplementary data

Journal Articles

I-387, a Novel Antimitotic Indole, Displays a Potent In vitro and In vivo Antitumor Activity with Less Neurotoxicity

Sunjoo Ahn, Charles B. Duke, III, Christina M. Barrett, Dong Jin Hwang, Chien-Ming Li, Duane D. Miller, James T. Dalton

Mol Cancer Ther (2010) 9 (11): 2859–2868.

DOI: https://doi.org/10.1158/1535-7163.MCT-10-0399

Published: 09 November 2010

View article

NARROW

Colchicine-binding site agent CH-2-77 as a potent tubulin inhibitor suppressing triple-negative breast cancer

An Orally Available Tubulin Inhibitor, VERU-111, Suppresses Triple-Negative Breast Cancer Tumor Growth and Metastasis and Bypasses Taxane Resistance

Abstract B037: Potential next-generation androgen receptor-targeted therapeutic for enzalutamide-resistant prostate cancer; In vivo characterization in immune-compromised SRG rats

Synergistic Combination of Novel Tubulin Inhibitor ABI-274 and Vemurafenib Overcomes Vemurafenib Acquired Resistance in BRAF^V600E Melanoma

I-387, a Novel Antimitotic Indole, Displays a Potent In vitro and In vivo Antitumor Activity with Less Neurotoxicity

Email alerts

AACR Journals

Colchicine-binding site agent CH-2-77 as a potent tubulin inhibitor suppressing triple-negative breast cancer

An Orally Available Tubulin Inhibitor, VERU-111, Suppresses Triple-Negative Breast Cancer Tumor Growth and Metastasis and Bypasses Taxane Resistance

Abstract B037: Potential next-generation androgen receptor-targeted therapeutic for enzalutamide-resistant prostate cancer; In vivo characterization in immune-compromised SRG rats

Synergistic Combination of Novel Tubulin Inhibitor ABI-274 and Vemurafenib Overcomes Vemurafenib Acquired Resistance in BRAFV600E Melanoma

I-387, a Novel Antimitotic Indole, Displays a Potent In vitro and In vivo Antitumor Activity with Less Neurotoxicity

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only

Synergistic Combination of Novel Tubulin Inhibitor ABI-274 and Vemurafenib Overcomes Vemurafenib Acquired Resistance in BRAF^V600E Melanoma